What is EP3560932A1 (delgocitinib) on Google Patents?
EP3560932A1 is a European patent publication that references delgocitinib. On Google Patents, you can use the publication number directly to pull up the full record (title, applicants/assignees, abstract, claims, and cited documents). The key practical step is to search Google Patents for EP3560932A1 (or delgocitinib EP3560932A1) to view the document and its related families.
Because you asked specifically about “EP3560932A1 delgocitinib Google Patents,” the most reliable way to interpret the patent is to open the Google Patents entry and read the abstract and claims, which indicate the exact invention scope covered by that publication.
How do I find delgocitinib patents on Google Patents besides EP3560932A1?
If you want to locate more delgocitinib-related filings on Google Patents, start from either:
- The compound name: search delgocitinib and then filter by “Publication date” or “Jurisdiction.”
- The assignee/applicant listed on EP3560932A1, then search that entity’s name on Google Patents.
- The “family members” link in the EP3560932A1 page to find corresponding US/WO/PCT publications and later continuations.
This approach helps you connect the European publication to broader global filings.
What details should you check on the EP3560932A1 Google Patents page?
To understand what EP3560932A1 covers, focus on:
- Abstract: the invention’s stated purpose.
- Claims: the legal scope (what is actually protected).
- Inventor and applicant/assignee: who filed it.
- Priority date: when the claim priority starts.
- Cited references: earlier art the examiner considered.
- Family members: other jurisdictions and publication numbers tied to the same priority.
If you tell me what you see in the abstract/claims (or paste the text), I can help interpret the likely subject matter and how it differs from other delgocitinib patents.
How long does a patent last (and what about EP publications)?
A patent term in Europe generally runs up to 20 years from the earliest priority date, subject to extensions and validity outcomes. EP publications (like EP3560932A1) are published patent applications/documents; grant status can differ by family member. The exact expiry or enforceability depends on:
- the earliest priority date,
- whether the application was granted,
- any term adjustments or patent term extensions applicable in the relevant country, and
- whether the patent is later invalidated or narrowed.
To answer precisely for EP3560932A1, you’d need the earliest priority date shown on the Google Patents record and the current legal status for that family member.
Can EP3560932A1 be challenged or invalidated?
Like any patent, it may face validity or scope challenges (for example, based on novelty, inventive step, or claim breadth) and enforcement disputes. The practical question people usually ask next is whether there are:
- opposition proceedings (before the EPO, if applicable),
- court cases in specific countries, or
- later amendments/grants narrowing claim scope.
Those details usually appear under “Legal events” on Google Patents. If you share the “Legal status” or “Events” section, I can summarize what it implies for enforceability.
What I need from you to give a concrete answer
I don’t have live access to Google Patents pages from this chat. If you paste any of the following from the EP3560932A1 Google Patents entry, I’ll summarize it accurately:
- the abstract,
- the independent claims (claim 1 and any claim dependents),
- the applicants/assignees and priority date,
- the “Family members” list, or
- the “Legal status / events” section.
If you want, tell me what you’re trying to do—e.g., “find the mechanism,” “identify the assignee,” “check expiration,” or “map it to other delgocitinib filings”—and I’ll tailor the extraction.